Envestnet Asset Management Inc. Has $14.47 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Envestnet Asset Management Inc. decreased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 12.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 302,613 shares of the biopharmaceutical company's stock after selling 42,665 shares during the period. Envestnet Asset Management Inc. owned 0.24% of Halozyme Therapeutics worth $14,468,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in shares of Halozyme Therapeutics by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after buying an additional 386,618 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Halozyme Therapeutics by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock valued at $85,254,000 after acquiring an additional 9,780 shares in the last quarter. Norges Bank acquired a new position in Halozyme Therapeutics during the 4th quarter worth $60,054,000. Arrowstreet Capital Limited Partnership grew its stake in shares of Halozyme Therapeutics by 141.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock worth $47,470,000 after purchasing an additional 581,475 shares in the last quarter. Finally, Boston Trust Walden Corp increased its holdings in shares of Halozyme Therapeutics by 28.0% during the fourth quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company's stock valued at $41,790,000 after purchasing an additional 191,465 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Trading Up 1.6 %

Shares of Halozyme Therapeutics stock traded up $0.92 on Tuesday, reaching $58.21. 1,429,561 shares of the company were exchanged, compared to its average volume of 1,428,026. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.97 and a fifty-two week high of $66.00. The firm has a market capitalization of $7.19 billion, a price-to-earnings ratio of 16.97, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The stock has a fifty day moving average price of $60.44 and a 200-day moving average price of $54.97.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. On average, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Buying and Selling

In other news, Director Jeffrey William Henderson sold 503 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total value of $32,217.15. Following the completion of the sale, the director now directly owns 33,108 shares of the company's stock, valued at $2,120,567.40. This represents a 1.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,200 shares of company stock valued at $1,286,568. Company insiders own 2.90% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. JPMorgan Chase & Co. increased their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a report on Monday. Wells Fargo & Company dropped their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Benchmark reaffirmed a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, Piper Sandler boosted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $62.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.